Table of Content

Archive

Winter 2019, Vol. 27 No. 4

Hong Kong J. Dermatol. Venereol. (2019) 27, 165-169


Original Article

An 11-year single centre experience with etanercept use in the treatment of moderate-to-severe psoriasis: a retrospective report

單一中心依那西普治療中至重度銀屑病的11年經驗:回顧性報告

CE Lim 林恩恩, HH Oon 溫惠文, WS Chong 張維盛

Abstract

Introduction: Biologics have significantly improved patient outcomes in psoriasis. This study describes our clinical experience using etanercept for the treatment of moderate-to-severe psoriasis. Methods: We conducted a retrospective analysis of patients with moderate-to-severe psoriasis started on etanercept from December 2004 to May 2016 at the National Skin Centre, Singapore. The primary measure of clinical response was 75% or greater improvement in percentage of affected body surface area (BSA) following 12 weeks of treatment. Results: Twelve out of twenty-three patients (52%) achieved at least 75% improvement in the percentage of BSA after 12 weeks of treatment. Etanercept was generally well tolerated. Conclusion: Etanercept for the treatment of psoriasis showed improvement in disease severity after 12 weeks in a substantial number of patients.

簡介:生物製劑可顯著改善銀屑病患者的病情。這項研究描述了我們使用依那西普治療中至重度銀屑病的臨床經驗。方法:我們對從2004年12月至2016年5月在新加坡國家皮膚中心開始使用依那西普治療的中至重度銀屑病患者進行了回顧性分析。臨床療效的主要衡量指標是治療12週後受影響的體表面積達百分之75或更高的改善。結果:在12週治療後,23名患者中有12名(52%)的體表面積百分比改善了至少75%。依那西普的耐受性一般良好。結論:依那西普治療銀屑病個案中,可見12週後許多患者的病情嚴重程度都有改善。

Keywords: Efficacy, etanercept, psoriasis, safety

關鍵詞: 功效、依那西普、銀屑病、安全